Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The association between antiretroviral therapy regimen and contraceptive failure among Malawian women living with HIV using injectable, progestin-based hormonal contraception.

Created on 13 Nov 2026

Authors

Karen Diepstra, Daniel Westreich, Mackenzie Cottrell, Audrey Pettifor, Mollie E Wood, Agatha Bula, Clara Lemani, John Chapola, Jennifer Winston, Katie R Mollan, Jill Hagey, Sam Phiri, Lameck Chinula, David W Erikson, Mina C Hosseinipour, Jennifer H Tang

Published in

Contraception. Pages 111761. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Drug-drug interactions between antiretroviral therapy (ART) and hormonal contraceptives are critical to understand for women with HIV (WWH) who do not desire pregnancy. One hormonal contraceptive commonly used among WWH in sub-Saharan Africa is depot medroxyprogesterone acetate (DMPA). We aimed to estimate the effect of efavirenz- versus dolutegravir-based ART on pregnancy incidence among Malawian WWH using DMPA contraception and ART as prescribed.
Using Family Planning and Antiretroviral Therapy (FP-ART) cohort data, we identified participants who initiated DMPA at enrollment and followed participants until DMPA or ART discontinuation, occurrence of first pregnancy, self-reported pregnancy intention of "now" or "in the next year", study dropout, or administrative censoring. We examined the time-varying exposure of ART regimen type (tenofovir disoproxil fumarate and lamivudine, with either efavirenz or dolutegravir). The outcome was clinically-detected pregnancy. We used inverse probability weights to fit marginal structural Poisson regression models to estimate incidence rate ratios (IRRs).
689 participants initiated DMPA at enrollment; 41 pregnancies were captured during 827 person-years of follow-up (crude incidence rate: 5.0/100 person-years, 95% confidence interval [CI]: 3.7, 6.7; crude efavirenz rate: 6.1 conceptions per 100 person-years, 95% CI: 4.3, 8.7; crude dolutegravir rate: 3.3 conceptions per 100 person-years, 95% CI: 1.8, 5.9). Restricted to person-time where DMPA was taken as prescribed, the crude incidence rate was 4.4/100 person-years (95% CI: 3.1, 6.2). The weighted IRR for consistently using efavirenz-based ART versus dolutegravir-based ART among those taking DMPA as prescribed was 1.90 (95% CI: 0.67, 5.40).
Among WWH who were taking DMPA as prescribed, we did not find evidence of an elevated pregnancy rate with continuous efavirenz- versus dolutegravir-based ART use, however the 95% confidence intervals were wide. Further understanding causes of contraceptive failure among WWH who use DMPA and ART is essential.
This work contributes to the growing evidence of possible drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and antiretroviral medications, such as efavirenz. This analysis underscores the safety of dolutegravir-based antiretroviral therapy.

PMID:
43020170
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement